Sabína Oreskáa b, Hana Štorkánováa b, Maja Špiritovića c d, Barbora Heřmánkováe, Michal Vrablı́kf, Karel Pavelkáa b, Ladislav Šenolta b, H Manna b, Jiří Vencovskýa b, Michal Tomčíka b
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Systemic inflammation, limited mobility, and glucocorticoid treatment in idiopathic inflammatory myopathies (IIM) can have a negative impact on intermediate metabolic pathways, especially on lipid metabolism.The aim of this study was to assess the differences in the lipid profile of IIM patients and healthy controls (HC) and the association with disease-specific features.133 patients with IIM (106 females; mean age 60.3; disease duration 2.2 years; DM 47 / PM 41 / IMNM 45) and 133 age-/sex-matched HC (106 females, mean age 60.2) were included. Patients with DM and PM fulfilled the Bohan/Peter criteria for PM/DM; patients with IMNM fulfilled the ENMC criteria. Levels of selected parameters of lipid metabolism were measured in sera. In IIM patients, disease activity, damage, and muscle involvement were evaluated (MITAX, MDI, MMT-8); comorbidities and current treatment were recorded. Data are presented as median.Several differences in disease activity, the dose of glucocorticoids, prevalence of comorbidities, and serum lipid levels were observed in IIM compared to HC, and among the three subtypes of IIM; the most significant changes were observed in IMNM. All the differences in lipid profile between IIM and HC, as well as the correlations of lipid profile parameters with disease-specific features in IIM patients, are demonstrated in the table 1.We have observed significant alterations in serum lipid parameters in our IIM patients compared to healthy age-/sex-matched individuals. Differences were also found among the three subtypes of IIM. These alterations were associated with laboratory parameters of disease activity and the current dose of corticosteroids.Table 1.Lipidogram in IIM patients compared to healthy controlsParameter of lipidogram, medianIIM(n = 133)DM(n = 47)PM(n = 41)IMNM(n = 45)HC(n = 133)p-valueIM-HC; DM-HC;PM-HC; IMNM-HCTC (mmol/L);5.795.365.656.35.14<0.001; 0.135; 0.040; <0.001TG (mmol/L);2.021.911.882.271.28<0.001; <0.001; 0.002; <0.001LDL-C (mmol/L);3.132.953.123.582.820.005; 0.436; 0.131; <0.001Apo-B (g/L);1.061.020.981.260.91<0.001; 0.160; 0.017; <0.001Non-HDL-C (mmol/L);4.44.254.155.13.9<0.001; 0.262; 0.040; <0.001Lp(a) (g/L);0.10.10.10.120.150.098; 0.733; 0.242; 0.032HDL-C (mmol/L);1.1221.131.181.361.20.913; 0.917; 0.503; 0.928Apo-A (g/L);1.71.761.751.681.80.073; 0.782; 0.267; 0.025AI (log(TG/ HDL-C);3.853.93.853.73.150.003; 0.425; 0.071; 0.002Significant correlations of lipid profile parameters and disease-specific features in all IIM patients (n=133)Correlated parametersSpear-man’s rp-valueCorrelated parametersSpearman’s rp-valueTC: Disease duration; LD; PED; Age; CK; Myoglobin-0.322; 0.343; 0.292; 0.193; 0.198; 0.249<0.001; <0.001; <0.001; 0.027; 0.025; 0.007non-HDL-C: Disease duration; LD; BMI; CK; Myoglobin; PED-0.303; 0.322; 0.202; 0.214;0.270; 0.275<0.001; <0.001; 0.027; 0.015;0.003; 0.002TG: Disease duration; PED; BMI-0.326; 0.316; 0.271<0.001; <0.001; 0.003HDL-C: CRP-0.2300.010LDL-: Disease duration; LD; Age; CK; Myoglobin;-0.310; 0.359; 0.212; 0.257; 0.289<0.001; <0.001; 0.015; 0.003; 0.002Apo-A: CRP; CK; Myoglobin-0.293; -0.214; -0,258<0.001; 0.016; 0.005Apo-B: Disease duration; LD; PED; Age; BMI; MMT-8; CK; Myoglobin; Glycemia-0.311; 0.348; 0.307; 0.220; 0.239; -0.214; 0.256; 0.307; 0.201<0.001; <0.001; <0.001; 0.012; 0.009; 0.017; 0.004; <0.001; 0.031AI: BMI0.2090.021Acronyms: TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein; Apo-B, apolipoprotein B; non-HDL-C, non-high-density lipoprotein (TC minus measured HDL-C); Lp(a), lipoprotein A; HDL-C, high-density lipoprotein; Apo-A, apolipoprotein A; AI, atherogenic index of plasma = log(TG/ HDL-C); LD, lactate dehydrogenase; PED, current prednisolone equivalent dose; CK, creatine kinase; BMI, body mass index; MMT-8, manual muscle testing-8; CRP, C-reactive proteinAZV NV18-01-00161A, MHCR-00023728, GAUK-312218None declared
TL;DRSeveral differences in disease activity, the dose of glucocorticoids, prevalence of comorbidities, and serum lipid levels were observed in IIM compared to HC, and among the three subtypes of IIM; the most significant changes were seen in IMNM. (Semantic Scholar)
